AC Immune director reports initial holdings

AC Immune SA director June Carl Howard has filed an initial ownership report showing equity interests in the company.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AC Immune SA director June Carl Howard has filed an initial ownership report showing equity interests in the company. Howard directly holds 50,988 common shares, including 49,988 common shares underlying outstanding restricted share units. In addition, Howard holds several fully vested or time‑vesting share options to purchase common shares at exercise prices ranging from $1.84 to $7.23, with expiration dates between 2030 and 2035. This filing records existing positions and does not reflect any new share purchases or sales.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider June Carl Howard

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 162,081 contracts (Direct); Common Shares — 50,988 shares (Direct)

Footnotes (3)

F1. Includes 49,988 common shares underlying outstanding restricted share units.
F2. The share option is fully vested.
F3. The share option will fully vest on June 17, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does June Carl Howard’s Form 3 filing for ACIU show?

The filing shows June Carl Howard’s existing equity holdings in AC Immune SA, including 50,988 common shares and multiple share option awards. It is an initial ownership report, not a record of new share purchases or sales.

How many AC Immune (ACIU) common shares does June Carl Howard hold?

June Carl Howard holds 50,988 AC Immune common shares directly. According to the disclosure, this figure includes 49,988 common shares underlying outstanding restricted share units, representing stock-based compensation that has been granted but not yet fully delivered.

What stock options does June Carl Howard report in AC Immune (ACIU)?

Howard reports several share options to buy AC Immune common shares with exercise prices from $1.84 to $7.23 per share. These options expire between 2030 and 2035, with at least one option already fully vested and another scheduled to fully vest on June 17, 2026.

Does June Carl Howard’s AC Immune (ACIU) Form 3 indicate any insider buying or selling?

The Form 3 does not indicate insider buying or selling activity. It lists Howard’s existing holdings of common shares, restricted share units, and share options as of the reporting date, serving as a baseline ownership statement upon becoming a reportable insider.

What do the footnotes in June Carl Howard’s AC Immune (ACIU) Form 3 explain?

The footnotes explain that 49,988 of the reported common shares are underlying outstanding restricted share units. They also clarify vesting status for option grants, noting one share option is fully vested and another will fully vest on June 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 12:19 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

June Carl Howard

(Last)

(First)

(Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE

PENNSYLVANIA

1015

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	50,988⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (right to buy)	⁽²⁾	11/22/2030	Common Shares	31,451	$5.04	D
Share Option (right to buy)	⁽²⁾	06/24/2031	Common Shares	12,865	$7.23	D
Share Option (right to buy)	⁽²⁾	06/23/2032	Common Shares	23,204	$3.15	D
Share Option (right to buy)	⁽²⁾	06/23/2033	Common Shares	37,168	$2.15	D
Share Option (right to buy)	⁽²⁾	06/30/2034	Common Shares	14,094	$4.23	D
Share Option (right to buy)	⁽³⁾	06/17/2035	Common Shares	43,299	$1.84	D

Explanation of Responses:

1. Includes 49,988 common shares underlying outstanding restricted share units.

2. The share option is fully vested.

3. The share option will fully vest on June 17, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthias Maurer, attorney-in-fact for Carl June	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR